Preview

Rational Pharmacotherapy in Cardiology

Advanced search

PLEIOTROPIC EFFECTS OF VITAMIN D

https://doi.org/10.20996/1819-6446-2016-12-2-227-233

Full Text:

Abstract

Review of clinical studies showing the pleiotropic effect of vitamin D with a detailed description of pathogenetic ways to implement these effects  is presented. Relation of vitamin D with cardiovascular diseases, kidney diseases, disorders of the immune and nervous systems, aging is discussed according to results of current researches.

About the Authors

O. M. Drapkina
State Research Center for Preventive Medicine, Moscow
Russian Federation


R. N. Shepel
State Research Center for Preventive Medicine, Moscow
Russian Federation


References

1. Zittermann A., Gummert F. J. Nonclassical Vitamin D actions. Nutrients 2010; 2(4): 408-25.

2. Kim D.H., Sabour S., Sagar U.N., et al. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 2008; 102: 1540-4.

3. Kassi E., Adamopoulos C., Basdra E.K., Papavassiliou A.G. Role of Vitamin D in atherosclerosis. Circulation 2013; 128: 2517-31.

4. Tomson J., Emberson J., Hill M., et al. Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12 000 deaths. Eur Heart J 2013; 34(18): 1365-74.

5. Holick M.F. Vitamin D and Health: Evolution, Biologic, Functions, and Recommended Dietary Intakes for Vitamin D. Clinic Rev Bone Miner Metab 2009; 7: 2-19.

6. Holick M.F. The vitamin D epidemic and its health conseguences. J Nutr 2005; 135: 11: 2739S-48S.

7. Lavie C.J., Dinicolantonio J.J., Milani R.V. Vitamin D and cardiovascular health. Circulation 2013; 128: 2404-6.

8. Menezes A.R., Lamb M.C., Lavie C.J., DiNicolantonio J.J. Vitamin D and atherosclerosis. Curr Opin Cardiol 2014; 29(6):571-7.

9. Li Y. C., Kong J., Wei M., et al. 1,25-Dihydroxy-Vitamin D3 is a negative endocrine regulator of the reninangiotensin system. Journal of Clinical Investigation 2002; 110(2):229-38.

10. Nadir M.A., Szwejkowski B.R., Witham M.D. Vitamin D and cardiovascular prevention. Cardiovasc Ther 2010; 28(4): 5-12.

11. Wu J., Garami M., Li Q., Gardner D.G. 1.25(OH)2D3 supress expression and secretion of atrial natriuretic peptide from cardiac myocytes. Am J Physiol 1995; 268: E1108-13.

12. Levin E.R., Gardner D.G., Sampson W.K. Natriuretic peptides. N Engl J Med 1998; 339: 321-8.

13. Schurgers L. J., Dissel P. E. P., Spronk H. M. H. et al. Role of Vitamin K and Vitamin K-dependent proteins in vascular calcification. Zeitschrift fur Kardiologie 2001; 90(3): 57-63.

14. Müller K., Haahr P. M., Diamant P. M., et al. 1,25-dihydroxy-Vitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 1992; 4(6):506-12.

15. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.

16. Galkina OV, Volkov MM, Smirnov AV, et al. Effects of vitamin D in patients with renal insufficiency. Meditsinskie Novosti 2011; 3: 35-6. In Russain (Галкина О.В., Волков М.М., Смирнов А.В., и др. Эффекты витамина D при почечной недостаточности. Медицинские Новости 2011; 3:35-6).

17. Isakova T1, Gutiérrez OM, Patel NM, et al. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr 2011;21(4):295-302.

18. Alborzi P., Patel N.A., Peterson C. et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52:249-55.

19. Patel T.V., Singh A.K. Role of Vitamin D in Chronic Kidney Disease. Semin Nephrol 2009; 29(2): 113-21.

20. Foltyn V. N., Bendikov I., J. De Miranda et al. Serine racemase modulates intracellular D-serine levels through an α,β-elimination activity. The Journal of Biological Chemistry 2005; 208(3): 1754-63.

21. Tan X., Li Y., Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. Journal of the American Society of Nephrology 2006; 17(2): 3382-93.

22. Tan X., Wen X., Liu Y. Paricalcitol inhibits renal inflammation by promoting Vitamin D receptor-mediated sequestration of NF-κB signaling. Journal of the American Society of Nephrology 2008; 19(9):1741-52.

23. Hayes C. E., Nashold F. E., Spach K. M., Pedersen L. B. The immunological functions of the Vitamin D endocrine system. Cellular and Molecular Biology 2003; 49(2): 277-300.

24. Asaka M., Iida H., Izumino K., Sasayama S. Depressed natural killer cell activity in uremia. Evidence for immunosuppressive factor in uremic sera. Nephron 1988; 49(4): 291-5.

25. Dudinskaya EN, Tkacheva ON. The role of vitamin D in the development of hypertension. Kardiovaskulyarnaya Terapiya i Profilaktika 2012; 11 (3): 77-81. In Russian (Дудинская Е. Н., Ткачева О. Н. Роль витамина D в развитии артериальной гипертензии. Кардиоваскулярная Терапия и Профилактика 2012; 11(3): 77-81).

26. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? British Journal of Nutrition 2003; 89(5): 552-72.

27. Kamen D.L., Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med 2010; 88: 441-50.

28. Liu M., Lee M., Cohen M., et al. Transcriptional activation of the Cdk inhibitor p21 by Vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes and Development 1996; 10(2): 142-53.

29. Schauber J., Dorschner R. A., Coda A. B. et al. Injury enhances TLR2 function and antimicrobial peptide expression through a Vitamin D-dependent mechanism. Journal of Clinical Investigation 2007; 117(3): 803-11.

30. O'Kelly J., Hisatake J., Hisatake Y., et al. Normal myelopoiesis but abnormal T lymphocyte responses in Vitamin D receptor knockout mice. Journal of Clinical Investigation 2002; 109(8): 1091-9.

31. Hullett D. A., Cantorna M. T., Redaelli C. et al. Prolongation of allograft survival by 1,25-dihydroxyVitamin D3. Transplantation 1998; 66(7): 824-8.

32. Brewer L.D., Thibault V., Chen K.C., et al. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 2001; 21(1): 98-108.

33. Ibi M., Sawada H., Nakanishi M., et al. Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacol 2001; 40(6): 761-71.

34. Cornet A., Baudet C., Neveu I., et al. 1,25-Dihydroxyvitamin D3 regulates the expression of VDR and NGF gene in Schwann cells in vitro. J Neurosci Res 1999; 53 (6): 742-6.

35. Li Y.C., Pirro A.E., Demay M.B. Analysis of vitamin D-dependent calcium-binding protein messenger ribonucleic acid expression in mice lacking the vitamin D receptor. Endocrinol 1998; 139(3): 847-51.

36. Losel R., Wehling M. Nongenomic actions of steroid hormones. Nongenomic actions of steroid hormones. Nature Revs Mol Cell Biol 2003; 4(1): 46-55.

37. Garcion E., Wion-Barbot N., Montero-Menei C.N., et al. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002; 13(3): 100-5.

38. Chen K.B., Lin A.M., Chiu T.H. Systemic vitamin D3 attenuated oxidative injuries in the locus coeruleus of rat brain. Ann N Y Acad Sci 2003; 993: 313-24.

39. Canthorna M.T., Hayes C.E., DeLuca H.F. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996; 93: 7861-4.

40. Brown J., Bianco J.I., McGrath J.J., Eyles J.J. 1,25-DihydroxyVitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Nuroscience Letters 2003; 343(2): 139-43.

41. Suzuki M., Yoshioka M., Hashimoto M., et al. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr 2013; 97(5):1004-13.

42. Chaves M., Toral A., Bisonni A., et al. Treatment with vitamin D and slowing of progression to severe stage of Alzheimer’s disease. Vertex 2014; 25(114): 85-91.

43. Willer C.J., Dyment D.A., Sadovnick A.D., et al. Timing of birth and risk of multiple sclerosis: Population based study. BMJ 2005; 330(120):120.

44. Munger K.L., Levin L.I., Hollis B.W., et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMAhttp://www.ncbi.nlm.nih.gov/pubmed/17179460 2006; 296(23):2832-8.

45. Kalueff A.V., Minasyan A., Keisala T., et al. Increased severity of chemically induced seizures in mice with partially deleted Vitamin D receptor gene. Neurosci Lett 2006; 394: 69-73.

46. Cannell J.J. Autism and vitamin D. Med Hypotheses 2008; 70: 750-9.

47. McGrath J., Saari K., Hakko H., et al. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr Res 2004; 67: 237-45.

48. Gloth III F.M., Alam W., Hollis, B. Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. J Nutr Health Aging 1999;3: 5-7.

49. Liu M., Lee M., Cohen M., et al. Transcriptional activation of the Cdk inhibitor p21 by Vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes and Development 1996; 10(2): 142-53.

50. Cordero J.B., Cozzolino M., Lu Y. et al. 1,25-DihydroxyVitamin D down-regulates cell membrane growthand nuclear growth-promoting signals by the epidermal growth factor receptor. The Journal of Biological Chemistry 2002; 277(41): 38965-71.

51. Welsh J. Targets of Vitamin D receptor signaling in the mammary gland. Journal of Bone and Mineral Research 2007; 22(2): 86-90.

52. Baldwin B. R., Timchenko N. A., Zahnow C. A. Epidermal growth factor receptor stimulation activates the RNA binding protein CUG-BP1 and increases expression of C/EBPbeta-LIP in mammary epithelial cells. Molecular and Cellular Biology 2004; 24(9): 3682-91.

53. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? British Journal of Nutrition 2003; 89(5): 552-72.

54. Garland C.F. Vitamin D for cancer prevention: global perspective. Ann. Epidemiol 2009; 19: 468-83.

55. Lieberman D.A., Prindiville S., Weiss D.G., Willett W. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA 2003; 290(22): 2959-67.

56. Garland C.F., Gorham E.D., Mohr S.B., Garland F.C. Vitamin D for cancer prevention: global perspective. Annals of Epidemiology 2009; 19(7): 468-83.

57. Drapkina OM, Shepel RN. Modern ideas about the role of telomeres and telomerase in the pathogenesis of hypertension. Arterial'naya Gipertenziya 2013; 19 (4): 290-8. In Russian (Драпкина О.М., Шепель Р.Н. Современные представления о роли теломер и теломеразы в патогенезе гипертонической болезни. Артериальная Гипертензия 2013; 19(4): 290-8).

58. Drapkina OM, Shepel RN. Telomeres and chronic heart failure. Kardiologia 2014; 54 (4): 60-7. In Russian (Драпкина О.М., Шепель РН. Теломеры и хроническая сердечная недостаточность. Кардиология 2014; 54(4): 60-7).

59. Cappuccio F.P., D’Elia L., Strazzullo P., Miller M.A .Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2010; 33: 414-20.

60. Cappuccio F.P., Taggart F.M., Kandala N.B., et al. Meta-analysis of short sleep duration and obesity in children, adolescents and adults. Sleep 2008; 31: 619-26.

61. Ikehara S., Iso H., Date C., et al. Association of sleep duration with mortality from cardiovascular disease and other causes for Japanese men and women: the JACC study. Sleep 2009; 32(3): 259-30.

62. Drapkina OM, Shepel RN. Telomeres and telomerase complex. The main manifestations of the genetic fault. Kardiovaskulyarnaya Terapiya i Profilaktika 2015; 1: 70-7. In Russian (Драпкина О.М., Шепель Р.Н. Теломеры и теломеразный комплекс. Основные проявления генетического сбоя. Кардиоваскулярная Терапия и Профилактика 2015; 1: 70-7).

63. Drapkina OM, Shepel RN Social health risk factors. Focus on education. Kardiologiya v Belarusi 2015; 5 (42): 51-62. In Russian (Драпкина О.М., Шепель Р.Н. Социальные факторы риска здоровья. Фокус на образование. Кардиология в Беларуси 2015; 5(42): 51-62).

64. Drapkina OM, Shepel RN. A diet low in salt: the pros and cons. Rational Pharmacotherapy in Cardiology 2015; 11 (2): 190-5. In Russian )Драпкина О.М., Шепель Р.Н. Диета с низким содержанием поваренной соли: за и против. Рациональная Фармакотерапия в Кардиологии 2015;11(2): 190-5).

65. Drapkina OM, Shepel RN. Duration of sleep: a modern view on the problem from the viewpoint of a cardiologist. Rational Pharmacotherapy in Cardiology 2015; 11 (4): 413-9. In Russian (Драпкина О.М., Шепель Р.Н. Продолжительность сна: современный взгляд на проблему с позиций кардиолога. Рациональная Фармакотерапия в Кардиологии 2015;11(4): 413-9).

66. Drapkina OM, Shepel RN Smoking, telomere length, and cardiovascular disease. Kardiologiia 2015; 55 (10): 85-9. In Russian (Драпкина О.М., Шепель Р.Н. Курение, длина теломер и сердечно-сосудистые заболевания. Кардиология 2015; 55(10): 85-9).

67. Drapkina OM, Shepel RN The length of telomeres, and cardiovascular disease: emphasis on chronic psychological stress. Kardiologiya: novosti, mneniya, obuchenie 2015; 2: 48-53. In Russian (Драпкина О.М., Шепель Р.Н. Длина теломер и сердечно-сосудистые заболевания: акцент на хронический психологический стресс. Кардиология: новости, мнения, обучение 2015; 2: 48-53).

68. Spyridopoulos I., Haendeler J., Urbich C., et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004; 110:3136-42.

69. Drapkina OM, Shepel RN. Omega-3 polyunsaturated fatty acids, and age-associated disease: reality and prospects. Rational Pharmacotherapy in Cardiology 2015; 11 (3): 309-16. In Russian (Драпкина О.М., Шепель Р.Н. Омега-3 полиненасыщенные жирные кислоты и возраст-ассоциированные болезни: реалии и перспективы. Рациональная Фармакотерапия в Кардиологии 2015; 11(3): 309-16).

70. Xu Q., Parks C.G., DeRoo L.A., et al. Multivitamin use and telomere length in women. Am J Clin Nutr 2009;89(6): 1857-63.

71. Richards J.B., Valdes A.M., Gardner J.P., et al. Higher serum vitamin D concentrations are associated with longer leukocyte telomere length in women. Am J Clin Nutr 2007; 86: 1420-1425.

72. Liu J.J., Prescott J., Giovannucci E., Hankinson S.E., Rosner B., Han J., et al. Plasma vitamin D biomarkers and leukocyte telomere length. Am J Epidemiol 2013; 177: 1411-7.

73. Hoffecker BM, Raffield LM, Kamen DL, Nowling TK. Systemic lupus erythematosus and vitamin D deficiency are associated with shorter telomere length among African Americans: a case-control study. PLoS One 2013;8:e63725.

74. Bikbov BT, Tomilina NA. Condition replacement therapy in patients with chronic renal failure in the Russian Federation in 1998-2009 years. Report to the Russian Register of renal replacement therapy. Nefrologiya i Dializ 2014; 16 (1): 11-127. In Russian (Бикбов Б. Т., Томилина Н. А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998-2009 гг. Отчет по данным Российского регистра заместительной почечной терапии. Нефрология и Диализ 2014; 16(1): 11-127).

75. Ramirez R., Carracedo J., Soriano S., et al. Stress-induced premature senescence in mononuclear cells from patients on long-term hemodialysis. Am J Kidney Dis 2005; 45: 353-9.

76. Borras M., Panizo S., Sarro F., et al. Assessment of the potential role of active vitamin D treatment in telomere length: a case-control study in hemodialysis patients. Clin Ther 2012; 34: 849-56.

77. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-47.

78. Valdes A.M., Andrew T., Gardner J.P., et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005; 366: 662-4.

79. Nawrot T.S., Staessen J.A., Gardner J.P., Aviv A. Telomere length and possible link to X chromosome. Lancet 2004; 363: 507-10.

80. Drapkina OM, Shepel RN. Physical inactivity century disease: physical inactivity as a risk factor for diseases of the cardiovascular system and premature aging. Kardiologiya: novosti, mneniya, obuchenie 2015; 3: 53-8. In Russian (Драпкина О.М., Шепель Р.Н. Гиподинамия болезнь века: низкая физическая активность как фактор риска заболеваний сердечно-сосудистой системы и преждевременного старения. Кардиология: новости, мнения, обучение 2015; 3: 53-8).


For citation:


Drapkina O.M., Shepel R.N. PLEIOTROPIC EFFECTS OF VITAMIN D. Rational Pharmacotherapy in Cardiology. 2016;12(2):227-233. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-2-227-233

Views: 497


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)